Purpose The PI3K/Akt signaling axis contributes to the dysregulation of many dominant features in breast cancer including cell proliferation, survival, metabolism, motility, and genomic instability. While multiple studies have demonstrated that basal-like or triple-negative breast tumors have uniformly high PI3K/Akt activity, genomic alterations that mediate dysregulation of this pathway in this subset of highly aggressive breast tumors remain to be determined. Methods In this study, we present an integrated genomic analysis based on the use of a PI3K gene expression signature as a framework to analyze orthogonal genomic data from human breast tumors, including RNA expression, DNA copy number alterations, and protein expression. In combination with data from a genome-wide RNA-mediated interference screen in human breast cancer cell lines, we identified essential genetic drivers of PI3K/Akt signaling.
Introduction
Breast cancer heterogeneity can be observed clinically by widely varying therapeutic responses and at a molecular level by the myriad of genetic alterations driving tumorigenesis [1] [2] [3] [4] [5] [6] . Clinically, triple-negative breast cancer (TNBC), which is largely synonymous with the basal-like molecular subtype of breast cancer, accounts for 15-20% of breast tumors representing *20,000 new cases and *10,000 deaths each year in the United States [3, 7] . Given the lack of drug-able targets expressed by TNBC tumors, including the lack of estrogen receptor (ER) and the HER2 oncogene, few therapeutic options exist beyond currently utilized cytotoxic therapies, and the overall prognosis for these patients remains poor.
Many previous studies, including The Cancer Genome Atlas (TCGA) project, have reported increased phosphatidylinositol-3-OH kinase (PI3K) signaling in basal-like tumors. This pathway mediates, among other processes, cell cycle progression and survival, [3, [8] [9] [10] and is highly activated in this subset of tumors despite a low incidence (*7%) of PIK3CA activation mutations. While studies from the TCGA and others have noted copy number alterations or mutations in PTEN (35%), INPP4B (30%) and activation of multiple receptor tyrosine kinases, including EGFR (7%), ERBB2 (4%), and IGFR1 (2%), in addition to other mutations that may affect aberrant PI3K signaling in basal-like tumors, it remains to be determined whether additional mechanisms may contribute to pathway activity and/or the observed lack of response to PI3K family inhibitors [3, 8, [11] [12] [13] [14] .
To identify genomic alterations mediating PI3K/Akt signaling, specifically those that may represent novel therapeutic targets and/or biomarkers to current therapies, we utilized an integrative genomic strategy based on experimentally derived gene expression signatures [6] . By analyzing orthogonal proteomic and genomic data from the TCGA in conjunction with data from a genome-wide RNAi proliferation screen in breast cancer cell lines, we identified SOX4 as a putative novel regulator of PI3K/Akt signaling and in vitro studies confirmed the role of this gene in mediating Akt phosphorylation.
Materials and methods

Gene expression data
RNA sequencing data (n = 1031) from human tumors (Supplemental Table 1 ) were acquired from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) and processed as previously described [15] . PAM50 classification as well as calculation of the PI3K [6, 16] , PIK3CA [17] , PTEN Deleted, and PTEN Wildtype [18] signatures was performed as previously described [1, 6, 19] . Illumina HT-29 v3 expression data for the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) project (n = 1992) was acquired from the European Genome-phenome Archive at the European Bioinformatics Institute (https://www.ebi.ac.uk/ega/), and data were median centered [4] . Expression data for a panel of 51 breast cancer cell lines was acquired from GEO (GSE12777) [20] . Affymetrix U133?2 data were MAS5.0 normalized using Affymetrix Expression Console (ver1.2.1.20), and log 2 transformed. Expression probes were collapsed using the median gene value with the GenePattern [21] module CollapseProbes.
Reverse Phase Protein Array (RPPA) data RPPA data were acquired (October 24, 2013) from The Cancer Proteome Atlas data portal (http://app1.bioinformatics. mdanderson.org/tcpa/_design/basic/index.html). Replicationbased normalized RPPA data (n = 733) containing expression levels for 187 proteins and phosphorylated proteins (Supplementary Table 1 ) were used to identify differentially expressed proteins. Samples were separated into high (top quartile) and low (all other) subgroups based on pathway score and a t test used to assess differences in expression for each protein. Additionally, a Spearman's rank correlation was used to compare the overall correlation between pathway activity and protein expression.
Affymetrix SNP 6.0 copy number data Affymetrix SNP 6.0-derived copy number data (Firehose run April 16, 2014) were acquired from the Firehose data portal (http://gdac.broadinstitute.org/) for the 1031 samples (Supplementary Table 1 ) for which both CN and gene expression data were available. Pathway-specific CN alterations were identified as previously described [6] . Briefly, a Spearman's rank correlation (both positive and negative) was used to compare gene-level segment scores with pathway activity score. Second, the frequency of copy number gains (including high-level amplification and gains) or losses (loss of heterozygosity or deletion), as determined by GISTIC 2.0 [22] , in samples with high (top quartile) and low (all others) pathway activity was calculated by a Fisher's exact test. To identify genes that were significant across both methods, a threshold of q \ 0.05 was set for validation and q \ 0.01 for discovery.
Genome-wide RNAi proliferation data
To identify genes required for cell viability in a pathwaydependent manner, data from a genome-wide RNAi screen in a panel of breast cancer cell lines were analyzed [6, 23] . The Gene Activity Ranking Profile (GARP) normalized data were obtained from the DPSC (Donnelly-Princess Margaret Screening Centre) data portal (http://dpsc.ccbr. utoronto.ca/cancer/index.html) and filtered to include those 27 cell lines for which gene expression data (GSE12777) were also available (acquired February 2013). A negative Spearman correlation was used to compare pathway score and GARP score for each sample to identify genes essential for pathway-dependent cell proliferation. A threshold of p \ 0.05 was considered significant.
Cell culture and siRNA knockdown HCC38, HCC1143, and MDAMB468 cells were purchased from the American Tissue Culture Collection (Manassas, VA, USA). Cells were cultured in either RPMI-1640 medium with 10% fetal bovine serum and 1% penicillin/streptomycin (HCC38 and HCC1143) or DMEM/F12 medium with 10% fetal bovine serum and 1% penicillin/streptomycin (MDAMB468). Cells were sub-cultured at 60-70% confluence for siRNA transfections. Lipofectamine RNAiMAX (ThermoFisher) was used to transfect cells with 40 nm of SMART pool siRNA targeting SOX4 (M011779010005) or scrambled control (D0012061305) according to manufacturer's instructions (Dharmacon) for 48 h prior to RNA or protein isolation.
Western blot
Cells were harvested using Triton lysis buffer containing 25 mM HEPES, 100 mM NaCl, 1 mM EDTA, 10% glycerol, and 1% Triton X-100 with 19 protease and phosphatase inhibitor added fresh prior to use. 50 lg of protein was loaded on 4-20% Mini-protean TGX gradient gel (BioRad) at 100 V for 2 h at room temperature and transferred onto nitrocellulose membrane at 100 V for 1 h at 4°C. The membranes were blocked using 5% milk solution, incubated with primary antibody against pAkt, total Akt, and beta-actin (Cell Signaling Technology) overnight at 4°C followed by incubation with HRP-conjugated secondary antibodies (Cell Signaling Technology) for 1 h at room temperature. The signal was developed using SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific), digitally imagined using the ChemiDoc Touch Imagining System (BioRad) and signaling intensity quantified by ImageJ software (https:// imagej.nih.gov/ij/).
Immunofluorescence
Cells were grown on coverslips, fixed with 4% paraformaldehyde in PBS, and permeabilized with 0.25% Triton X-100 in PBS for 8 min at room temperature. Cells were blocked in 1% BSA in PBS with 0.05% Tween 20 for 45 min at room temperature, incubated with anti-SOX4 (Santa Cruz, sc-17326) and anti-pAKT (Cell Signaling, 9271S) antibodies (1 h, room temperature), and then incubated with fluorochrome-labeled secondary antibodies for 1 h (room temperature). The coverslips were counterstained with DAPI and imaged with a Nikon Eclipse TE-2000U fluorescent microscope.
Quantitative real-time PCR
Total RNA was isolated using RNeasy plus Mini Kit (Qiagen) and cDNA was synthesized using the QuantiTect Reverse Transcription kit (Qiagen). Quantitative PCR (qPCR) was performed and analyzed using Applied Biosystems 7500 real-time thermal cycler system. Human SOX4 primer sequences are as follows [19, 24] were determined (Fig. 1a) . Although each signature was independently developed [6, 17, 18] , consistent patterns of pathway activity were observed across molecular subtypes with basal-like tumors being characterized by uniformly high levels of PI3K activity; increased signaling was also observed in HER2-Enriched (HER2E) and Luminal B (LumB) tumors, and significant differences were noted between each subtype ( Supplementary Fig. 1 ). Despite the fact that each signature was developed using different strategies, identifying differentially expressed genes when comparing either GFP expressing cell lines to mutant [17] or wild-type [6, 16] PIK3CA expressing cells or by comparing PTEN wild-type and deleted tumors [18] , signature scores were moderately concordant (r = 0.4-0.67) across the data ( Fig. 1b; Supplementary Fig. 2 ).
Focusing on the PI3K signature [6, 16] , we confirmed the ability of the mRNA signature to accurately assess functional activation of the pathway by examining relationships between the gene expression signature score and proteins and phosphoprotein expression. Analysis of Reverse Phase Protein Array (RPPA) data from breast tumors (n = 733), using both a Spearman correlation (comparing pathway score to protein expression level) and t test (top quartile against all other samples), confirmed that tumors with a high PI3K score have significantly lower levels of PTEN and INPP4B protein expression, consistent with role of these proteins as negative regulators of PI3K/Akt signaling. Despite lower levels of total Akt and no differences in the expression of the p110-alpha or p85 kinase subunits, tumors with high pathway score expressed significantly higher levels of phosphorylated (p) Akt at S473 and T308 ( Fig. 1c ; Supplementary Table 2 ). In addition, a number of known drivers of PI3K activity, including EGFR (pY1068 and pY1173), FOXM1, NOTCH1, cKIT, SYK, SRC (pY416), and c-MET (pY1235), had significantly higher levels of protein expression in tumors with a high PI3K score. Importantly, we also observed increased levels (p \ 0.05) of activated Akt substrates including PRAS40 (pT246), p27 (pT198), and YB1 (pS102) as well as further down-stream targets S6 (pS235-S236 and pS240-S244) and 4EBP1 (pT70) ( b PI3K pathway gene expression signatures are strongly correlated as calculated by a Pearson correlation. c PI3K signature (n = 733) corresponds with protein and phosphorylated protein expression of PI3K/Akt signaling pathway components. A t test (double dagger) was used to assess protein expression levels between the top quartile and all other samples, and a Spearman's rank correlation (single dagger) was used to assess the overall relationship between pathway score and RPPA expression level Identification of copy number alterations associated with PI3K signaling
We next sought to identify PI3K-specific copy number (CN) alterations (CNA), including known and potential novel drivers of pathway activity (Fig. 2a) . Using our previously published strategy [6] , breast tumor samples (n = 1031) from the TCGA project were dichotomized into those with high (top quartile) or low (all others) pathway score, and the frequency of copy number gains (including high-level amplification and gains) or losses (including homozygous deletion and loss of heterozygosity) was calculated for each group (Fig. 2b) using a Fisher's exact test (Fig. 2c) . Second, a Spearman Rank Correlation was used to assess the overall relationship between PI3K pathway score and gene-level segment value (Fig. 2c) . To reduce potential false positives associated with either strategy alone, we focused on those alterations that were significant (q \ 0.05), in both analyses; genes with an increased incidence of CN gains in samples with high PI3K pathway activity (top quartile) and a positive correlation with pathway activity were considered putative drivers of PI3K signaling, whereas those genes with an increased frequency of CN losses in tumors with a high PI3K score and a negative correlation were considered potential repressors of PI3K activity. These analyses allow for the identification of chromosomal alterations that are uniquely evident in the context of PI3K ; q Spearman = 4.0 9 10
-10
). Beyond PIK3CA amplification, we also identified CNA (q \ 0.05) of known drivers of PI3K signaling including amplification of KRAS, PTK2, and FOXM1 as well as losses of pathway inhibitors PTEN, INPP4B, and PIK3R1 (Fig. 2b,  Supplementary Table 3) . Collectively, these data suggest that this strategy is able to identify CNA of known PI3K signaling components and may identify CNA of novel regulators of this pathway.
Identification of potential essential, novel regulators of PI3K pathway activity
Our previous results identified DNA copy number aberrations that correlate with PI3K activity (Fig. 2) . By analyzing functional data from a genome-wide RNAmediated interference (RNAi) screen, we are able to identify specific genes within each amplicon that are essential for cell viability in a pathway-dependent manner. For these analyses, we employed data from a genome-wide RNAi proliferation screen (*16 k genes) performed in a panel of 27 breast cancer cell lines [23] for which matching mRNA expression data (GSE12777) was available (Fig. 2) . For each cell line, the PI3K pathway score was calculated, and a negative Spearman's rank correlation was used to identify those genes required for cell proliferation in a PI3K-dependent manner. Our analyses identified known PI3K/Akt signaling components including PYK2 (Fig. 3a , p = 0.003) [25] as well as both EIF4E (Fig. 3b , p = 0.004) and RPS6 (Fig. 3c , p = 0.05), which are prominent down-stream targets of Akt activity thereby validating this strategy.
Next, we used these functional data to prioritize candidate genes within each amplicon associated with PI3K activity. To do so, we compared the subset of genes that were amplified in a greater percentage (q \ 0.01) of samples with high PI3K pathway activity, had a positive correlation between PI3K signature score and CN segment score (q \ 0.01), and were required for cell viability (p \ 0.05) in a PI3K-dependent manner (Fig. 3d) . This subset of genes was further restricted to those that also showed a positive correlation between DNA CN status and mRNA expression (Fig. 3e) based on the reasoning that a potential regulator of pathway activity must not only be amplified but also have increased mRNA expression (Supplementary Table 4 ). Of the identified candidate genes, several, including NEDD9, which has been reported [26] to serve as a scaffolding protein for Akt and required for breast cancer genesis, have been reported to play a role in PI3K/Akt signaling. These data provide evidence that this strategy has the potential to identify both known and potentially novel mediators of PI3K/Akt signaling.
SOX4 is a putative driver of PI3K/AKT signaling Among the candidate, genes identified on chromosome 6p22 was SOX4 (sex-determining region Y-related highmobility-group box transcription factor 4), which is a previously described oncogenic transcription factor that has been reported to correlate with a poor clinical outcome in human breast cancer and other cancers [27, 28] . We determined that SOX4 CN positively correlated with PI3K score (Fig. 4a) and mRNA expression (Fig. 4b) . In total, 41.5% of tumors with high pathway activity (top quartile) were characterized by SOX4 CN gain compared to 22 .6% of all other samples (q = 2.5 9 10 -08 ) (Fig. 4c ). This appears to be largely a subtype-specific event as 68.1% of tumors with high PI3K activity and amplified SOX4 were basal-like (Fig. 4d) ; in total, 57.2% of all basal-like tumors were characterized by SOX4 amplification (Supplementary Fig. 3 ). Furthermore, SOX4 amplified tumors had the highest levels of SOX4 mRNA (Fig. 4e , p = 4.0 9 10 -23, ANOVA; p \ 0.0001) and highest levels of PI3K activity ( Supplementary Fig. 4 , p = 3.7 9 10 -08 , ANOVA; p \ 0.0001). Analyses of the METABRIC [4] dataset (n = 1992) demonstrated a comparable significant correlation between PI3K pathway score and SOX4 expression (r = 0.42, p = 2.6 9 10 -87 ), and SOX4 CN status (r = 0.23, p = 1.1 9 10 -24 ), respectively, as well as between SOX4 expression and CN (r = 0.27, p = 1.5 9 10 -34 ), thereby validating our findings in an independent cohort ( Supplementary Fig. 5 ). Importantly, our analyses of data from a genome-wide RNAi screen demonstrated that breast cancer cell lines with high PI3K activity have a greater dependency (p = 0.048) on SOX4 than cell lines with low PI3K activity (Fig. 4f) .
Finally, examining the coincidence of SOX4 amplification with copy number alterations of known drivers of PI3K signaling demonstrated that the frequency of SOX4 amplification in tumors with high (or low) PI3K activity was comparable (q \ 0.05) to that of PIK3CA (50.4 vs. 25.0%), PTEN (46.9 vs. 25.5%), or INPP4B (37.6 vs. 24.8%) CNA (Fig. 4a) . These alterations, however, were neither mutually inclusive nor mutually exclusive as SOX4 was solely altered (19.1%) at a comparable frequency to PTEN (23.6%) or INPP4B (18.7%) loss, or PIK3CA gain (21.7%) alone (Supplementary Fig. 6 ).
Increased PI3K/AKT signaling in breast tumor samples with amplified SOX4
We next determine whether patients with amplified SOX4 are characterized by increased expression of Akt substrate proteins relative to those tumors that have a normal copy number. Analysis of RPPA-based protein expression in breast tumors with amplified (n = 198) and normal (n = 431) SOX4 (Fig. 5a ) demonstrated up-regulation of pAkt substrates in SOX4-amplified tumors including pPRAS40 pT246 (p = 0.01); p27 pT157 (p = 0.004) and pT198 (p = 1.8 9 10 )] and pS6 at pS235-pS236 (p = 0.001) and pS240-S244 (p = 0.0007) were also up-regulated in SOX4-amplified tumors. Consistent with these findings, we determined that tumors characterized by loss of PTEN (n = 227), relative to samples with normal PTEN (n = 436), showed consistent up-regulation of this subset of Akt substrates and down-stream target proteins (Fig. 5b) . As such, these data support the association of SOX4 with altered PI3K/ Akt signaling.
SOX4 mediates PI3K/Akt signaling in basal-like breast cancer
In order to confirm that SOX4 contributes to altered PI3K signaling, we utilized gene expression data from a panel of 51 breast cancer cell lines (GSE12777) to identify those with the highest PI3K score (Supplementary Fig. 7 have high PI3K signature score and high SOX4 expression, whereas MDAMB468 cells have high PI3K activity but low (below the dataset median) SOX4 expression. In addition to high PI3K activity, each of these cell lines are characterized by either loss of PTEN (HCC38) or EGFR activation (HCC1143) or both PTEN loss and EGFR activation (MDAMB468). Using these cell lines, we examined the effects of siRNA-mediated silencing of SOX4 on Akt phosphorylation. Quantitative Real-time PCR (qRT-PCR) confirmed that cells transfected with pooled siRNA comprised a panel of four individual siRNA targeting SOX4 resulted in a significant decrease in SOX4 expression in HCC38 (90%, p = 0.002, paired t test), HCC1143 (79%, p = 0.003, paired t test), and MDAMB468 (70%, p = 0.0001, paired t test) cells, respectively, relative to scrambled control (siC)-transfected cells (Fig. 6a) . Loss of SOX4 resulted in a significant reduction in Akt phosphorylation in both HCC38 and HCC1143, while no change in pAkt levels were observed in MDAMB468 cells; total Akt or b-actin levels were unaffected (Fig. 6b) . Quantitative analyses of pAkt levels relative to total Akt (Fig. 6c) demonstrated that loss of SOX4 resulted in a 54-56% reduction in pAkt levels, relative to siC-treated cells, in HCC38 (p = 0.0008) and HCC1143 (p = 0.005), respectively, while no quantifiable change was observed in MDAMB468 cells (p = 0.53).
Analysis of siC and siSOX4-treated cells by immunofluorescent microscopy (IF) further demonstrates that SOX4 is largely undetectable in siSOX4-treated HCC38 cells, and this loss of SOX4 protein expression corresponds with nearly an equal reduction in the levels of pAkt (Fig. 6d) . Interestingly, the subset of siSOX4-treated HCC38 cells which retain detectable levels of SOX4 also express pAkt suggesting that -23 ). (F) SOX4 is essential for cell viability is breast cancer cell lines with high PI3K pathway activity. Higher expression of the PI3K Score is associated with lower SOX4 shRNA abundance (Spearman correlation, p = 0.048) our western blot analyses may underestimate the total effect of SOX4 on pAkt levels and when compared on a cell to cell basis, SOX4 has a more dramatic effect on the phosphorylation of Akt. As shown in Supplementary Fig. 8 , similar effects on pAkt levels were observed after SOX4 silencing in HCC1143 cells.
Discussion
PI3K/Akt/mTOR signaling regulates many predominant features of cancer including cellular proliferation, survival, metabolism, motility, and genomic instability [8, 9] . This pathway not only contributes to tumor development, but also plays an essential role in regulating therapeutic resistance in breast cancer [29] [30] [31] . Not surprisingly, there has been a significant effort to elucidate mechanisms regulating PI3K signaling in order to identify potential therapeutic targets and/or biomarkers to current therapies.
Improper activation of this pathway occurs through various molecular mechanisms including, among others, PIK3CA activating mutations; PTEN silencing mutations; and/or copy number changes in PIK3CA, PTEN, INPP4B, or AKT2, depending on the type and/or subtype of cancer [8] [9] [10] . In breast cancer, approximately 45% of patients are characterized by PIK3CA-activating mutations [1, 3] ; however, these alterations are largely limited to LumA tumors and the link between these mutations and pathway activation is unclear as there is no correlation with known markers of pathway activity including pAkt, pS6, or p4EBP1 [3, [32] [33] [34] . In contrast, basal-like or TNBC tumors are characterized by increased PI3K activity and have increased expression of these markers despite the fact that these tumors rarely have PIK3CA activating mutations [3, 12] . While clinical studies have demonstrated that the combination of everolimus plus exemestane resulted in an improved prognosis for patients with advanced stage, ER? luminal breast cancer [35] [36] [37] , similar success has not been achieved in TNBC.
In the current study, we sought to identify genomic alterations that contribute to PI3K/Akt signaling and which may represent putative therapeutic opportunities. To address this challenge, we analyzed genomic data from more than 1000 breast tumor samples from the TCGA [1, 3] within the framework of an experimentally derived PI3K gene expression signature [6] . These in silico analyses identified SOX4 as putative novel regulator of PI3K signaling, and this association was validated in an independent cohort of nearly 2000 breast tumor samples [4] . Since altered expression of this gene predominantly occurs in basal-like tumors, these data, consistent with previous studies demonstrating increased SOX4 expression in TNBC, suggest that this may be a subtype-specific event [38] . SOX4 is a member of the group C family of SOX transcription factors which play an essential role in development but are reported to be over-expressed in many human cancers, including breast cancer where expression correlates with tumor grade, stage, and prognosis [27, 28, 39] . Previous studies have reported that SOX4 contributes to tumor development and progression through a number of mechanisms. SOX4 has been shown to be essential in maintenance of stemness in cancer initiating cells, in driving cell proliferation, by promoting cell migration and metastasis and, more recently, through induction of epithelial-to-mesenchymal transition (EMT) in breast cancer [38, [40] [41] [42] [43] . While these previous studies have demonstrated a significant role for SOX4 in tumor development, the current study is first to identify SOX4 as a mediator of PI3K/Akt signaling in breast cancer. These results are consistent with recent work that demonstrates a role for SOX4 in regulating PI3K activity in Ph? ALL (Acute Lymphoblastic Leukemia) [44] .
Experimental studies demonstrate that SOX4 regulates pAkt expression in breast cancer cell lines with high SOX4 expression irrespective of whether these cells are characterized by loss of PTEN or activation of EGFR. While the exact mechanism by which SOX4 modulates PI3K/Akt signaling remains to be determined, a number of recent studies offer insight into several potential mechanisms. The role of SOX4 as a transcription factor suggests that its effect on the PI3K pathway is mediated through regulation at the transcript level. However, given that our data demonstrate a clear loss of phosphorylated Akt in the absence of SOX4 expression, but no discernible difference in total Akt, the effect of SOX4 on signaling appears to be up-stream of Akt. It was recently reported that SOX4 cooperates with PTEN loss to mediate prostate cancer tumorigenesis [45] ; however, given that we see a comparable effect on SOX4-mediated Akt phosphorylation in both PTEN normal and PTEN deleted cells, it is unclear whether this is also true in breast cancer. The potential does exist that SOX4 could mediate PTEN activity. In fact, studies in hepatocellular carcinoma recently reported that SOX4 can modulate HUNK kinase (Hormonally up-regulated Neu-associated kinase) expression, which itself, has been shown to regulate Akt signaling in breast cancer by repressing PTEN activity [46, 47] . Unfortunately, we see no difference in HUNK mRNA expression in SOX4 amplified and normal breast tumors.
Alternatively, a number of studies have suggested that SOX4 can mediate activation of potential up-stream drivers of PI3K signaling including transcriptional activation of EGFR [48] . Despite these findings in prostate cancer, we see a SOX4-mediated effect on pAkt levels in both EGFRactivated and normal breast cancer cell lines. Moreover, we do not see a difference in pEGFR protein expression in SOX4-amplified or normal breast tumors. Although these data do not eliminate the possibility that SOX4 mediates its effect on pAkt through EGFR, or another receptor tyrosine kinase, it suggests that alternative breast cancer-specific mechanisms may exist. Perhaps not surprising, recent analyses have also shown little concordance between genes regulated by SOX4 across tissues type including prostate, lung, hepatocellular carcinoma, and adenoid cystic carcinoma [27, 28] . Thus, these results suggest the effects of SOX4 on PI3K signaling may be affected by tissue specific features. As such, additional studies must be undertaken to delineate these breast cancer-specific mechanisms.
Collectively, our cross-platform analyses of orthogonal genomic and proteomic data, along with in vitro studies, have identified and validated SOX4 amplification as a mediator of PI3K/Akt signaling in breast cancer. While the precise mechanisms by which SOX4 modulates PI3K activity in breast cancer remain unknown, our data, in combination with previous studies, suggest not only that an emphasis should be placed on elucidating these mechanisms but also that SOX4, or its down-stream targets, may be a putative therapeutic target and/or biomarker in breast cancer patients whose tumors are characterized by high PI3K activity.
